Quantcast

Latest vemurafenib Stories

2014-06-10 12:30:10

MADISON, N.J., June 10, 2014 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today introduced a new cancer test service based on the FDA-approved THxID(®)-BRAF test from bioMerieux, a world leader in the field of in vitro diagnostics. The THxID(®)-BRAF test is a companion diagnostic for two treatments for melanoma. The test is intended to be used as an aid in selecting patients with melanoma whose tumors carry the BRAF...

2014-06-03 11:21:00

University of Texas M. D. Anderson Cancer Center Early but promising results lead to Phase II national trial In an aggressive disease known for poor response rates, researchers from The University of Texas MD Anderson Cancer Center found patients with advanced colorectal cancer responded well to a combination therapy of the drugs vermurafenib, cetuximab and irinotecan. The Phase I trial, presented Saturday, May 31 in a poster discussion at the American Society of Clinical Oncology's...

2014-03-26 12:26:20

The Highest Percentage of Non-Prescribers Anticipate Prescribing Tafinlar and Mekinist Within the Next One to Three Months, According to Findings from Decision Resources Group BURLINGTON, Mass., March 26, 2014 /PRNewswire/ -- Decision Resources Group finds that at six months post-launch in the United States, 45 percent of surveyed U.S. medical oncologists have prescribed GlaxoSmithKline's BRAF inhibitor Tafinlar for BRAF-mutation-positive unresectable or metastatic melanoma compared with 28...

2014-01-16 14:22:49

University of Leicester researchers deploy 'precision medicine' to successfully target advanced form of leukaemia with skin cancer drug A team of scientists from the University of Leicester has demonstrated a novel treatment for Hairy Cell Leukaemia (HCL), a rare type of blood cancer, using a drug administered to combat skin cancer. The research, which is published today (Thursday 16 January) in the New England Journal of Medicine, indicates Vemurafenib, a BRAF inhibitor that has been...

Newly Discovered Molecular Targets May Treat Difficult Melanomas
2014-01-01 08:56:37

redOrbit Staff & Wire Reports - Your Universe Online A recently-published study in the journal Clinical Cancer Research supported by the Stand Up To Cancer (SU2C) charitable foundation has identified new molecular targets which could potentially result in new remedies for difficult-to-treat melanomas. A team of investigators, including Dr. Jeffrey A. Sosman of the Vanderbilt-Ingram Cancer Center and Dr. William Pao of the Vanderbilt University School of Medicine, found two novel...

Study Finds Drug-Resistant Melanoma Treatments May Be Enhanced
2013-11-22 09:27:11

April Flowers for redOrbit.com - Your Universe Online More than 8,000 Americans are killed each year by melanoma -- the deadliest form of skin cancer. The presence of mutations in a gene known as the BRAF gene drives approximately 40 percent of advanced melanoma tumors. New medications, called BRAF inhibitors, have shown an ability to rapidly shrink melanoma tumors, however BRAF-mutated tumors often resist early treatment and only partially respond to BRAF inhibitors, which leaves...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related